Venous Leg Ulcer
Conditions
Interventions
Control group:(1) Take Diosmin Tablets (Nanjing Chia Tai Tianqing Pharmaceutical Co., Ltd., National Drug Approval No. H20058471) 0.9g orally twice a day. (2) After routine disinfection of the wound,
anticoagulant, antiplatelet, vasodilator drugs are applied according to the patients condition
for severe infections, antibiotics are used based on the results of drug sensitivity tests.
Experimental group:In the treatment of the control group, Qimiao Lianzao Yin (12g of Phellodendron amurense, 9g of Atractylodes macrocephala, 30g of Coix Seed, 15g of Poria cocos, 12g of Atractylodes
Sponsors
Affiliated Hospital of Shandong University of Traditional Chinese Medicine
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: (1) Patients meeting the diagnostic criteria for VLU and Liangchuang. (2) Patients diagnosed with the Dampness-Heat Descending Syndrome according to Traditional Chinese Medicine (TCM) pattern differentiation. (3) Patients classified as clinical grade C6 or C6r according to the CEAP classification. (4) Patients aged between 18 and 80 years (18 < age = 80). (5) Wound area = 25 cm² (for patients with multiple wounds, the larger wound will be selected). (6) Patients who have signed the informed consent form. (7) Patients with good compliance, capable of cooperating with treatment and observation.
Exclusion criteria
Exclusion criteria: (1) Patients with ulcers of other etiologies, such as arterial, vasculitic, or radiation-induced ulcers, are excluded. (2) Patients with severe comorbidities, including cardiac, cerebrovascular, hepatic, or renal insufficiency. (3) Patients with concurrent infectious diseases, malignancies, autoimmune diseases, hematological disorders, connective tissue diseases, severe psychiatric disorders, severe hypoproteinemia, or electrolyte imbalances. (4) Pregnant or lactating women. (5) Patients with severe lower limb lymphedema. (6) Patients with a history of allergy to the study medication.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Wound healing rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Tumor Protein p53 ;Mitogen-Activated Protein Kinase 3; | — |
Countries
China
Contacts
Public ContactYannan Wang
Affiliated Hospital of Shandong University of Traditional Chinese Medicine
Outcome results
None listed